Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediWoundMDWD +0.30%56 Cash-to-Debt is 4.11 as of Jun. 2026, which is 68% below its 10-year median of 12.98. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $11.09 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,398 Biotechnology companies, MediWound ranks worse than 56.65% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MediWound's cash to debt ratio for the quarter that ended in Jun. 2026 was 4.11.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, MediWoundcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for MediWound's Cash-to-Debt or its related term are showing as below:
MDWD'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.87 Med: 12.98 Max: No Debt
Current: 4.11
During the past 13 years, MediWound's highest Cash to Debt Ratio was No Debt. The lowest was 1.87. And the median was 12.98.
MDWD's Cash-to-Debt is ranked worse than 56.65% of 1398
companies
in the Biotechnology industry
Industry Median: 6.575
vs MDWD: 4.11
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
MediWound Cash-to-Debt Related Terms
MediWound Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for MediWound's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, MediWound's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediWound Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediWound's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where MediWound's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediWound (MDWD) has a Cash-to-Debt of 4.11 as of Jun. 2026. This is 68% below median its historical median of 12.98. Over the past decade, MediWound's Cash-to-Debt has ranged from 1.87 to 10,000.00. According to the industry distribution chart, MediWound ranks #792 out of 1398 companies in the Biotechnology industry, placing it in the top 56.7%.
Is MediWound's Cash-to-Debt too high?
MediWound's current Cash-to-Debt of 4.11 is 68% below median its 10-year median of 12.98. Over the past 10 years, this metric has ranged from a low of 1.87 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.58. MediWound's value of 4.11 is 37.5% below this industry median. Based on the distribution chart, MediWound ranks #792 out of 1398 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's Cash-to-Debt compare to LENZ and OTLK?
According to the Biotechnology industry distribution chart, MediWound ranks #792 out of 1398 companies for Cash-to-Debt. This places MediWound in the lower half of its industry. The industry median Cash-to-Debt is 6.58. MediWound's value of 4.11 is 37.5% below this benchmark. Historically, MediWound's own Cash-to-Debt has ranged from 1.87 to 10,000.00 over the past decade. While the company's 10-year median is 12.98 vs. the industry median of 6.58, MediWound has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.58, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediWound's current Cash-to-Debt of 4.11 is 37.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediWound's current Cash-to-Debt is 4.11, which is 68% below median its own 10-year median of 12.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $11.09, compared to a current price of $13.31 — trading 20% above its estimated fair value. The current Cash-to-Debt is 4.11, which is 68% below median its 10-year median of 12.98 and 37.5% below the Biotechnology industry median of 6.58. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For MediWound (MDWD), the current Cash-to-Debt is 4.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediWound (MDWD) Overvalued in 2026?
Based on GuruFocus' analysis, MediWound stock appears to be overvalued.
The current stock price of $13.31 is trading 20% above its estimated GF Value™ of $11.09.
GuruFocus considers MediWound to be Modestly Overvalued.
Key valuation signals for MDWD:
Cash-to-Debt: 4.11 (68% below median its 10-year median of 12.98)
GF Value™: $11.09 vs. price of $13.31 (20% above fair value)
Industry Position: 37.5% below the Biotechnology median (#792 of 1398)
No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score
Get the complete analysis for MDWD
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDWD has been successfully added to your 
